The most numerous, branched and closer to the population is therapeutic service of the Stavropol territory. In the structure of doctors of all specialities of physicians, therapists make up about 10 percent. Therapeutic service is constantly being improved, the priority becomes prophylactic direction. This article presents some results of work of therapeutic service of the Stavropol territory in recent years.

This review summarizes the results of the pilot project «Prophylactic mass screening examinations of adult population», which had been held in October–November 2012 in the Moscow region, the organization of which was attended by specialists of the Moscow regional center of medical prevention.

Proton pump inhibitors take the leading place in treatment of acid-related diseases of the digestive system. Compared to other proton pump inhibitors pantoprazole (Controloc) has higher chemical stability and less potential for interaction with hepatic oxidase system, which depends on cytochrome P450. Pantoprazole (Controloc) does not accumulate, and in case of repeated drug intake during the day pharmacokinetics does not change. So, there is no need for special selection of the dose of pantoprazole in elderly patients or in patients with renal insufficiency and with moderate hepatic impairment.

Clinical observation of outpatients and deceased patients with atrial fibrillation, as well as implementing the Recommendations of the Russian Society of Cardiology and the European Society of Cardiology for the management of patients with atrial fibrillation were discussed during Moscow district therapists’ conference and online broadcast. All participants in the interactive format considered prevention of thrombotic events (such as strokes) by means of modern antithrombotic therapy using novel oral anticoagulants.

Aim of this study was to estimate mortality and frequency of recurrent cardiovascular events, dynamics of neurological deficit, endothelial dysfunction and renal function in patients with the first-time ischemic stroke treated with simvastatin 40 mg/day in acute period of the disease. Simvastatin 40 mg/day (Zokor forte) prescribed along with neuroprotective and antihypertensive treatment in acute stage of ischemic stroke leads to lowering of recurrent cardiovascular events number, positive dynamics of neurological status, regression of endothelial dysfunction, associated with improved renal function.

We studied dependences of structural and functional changes of the arteries in 232 patients with connective tissue dysplasia. The increase of indicators of arterial stiffness and endothelial function in young patients with connective tissue dysplasia. With age, those with connective tissue dysplasia remain higher values of arterial stiffness, compared with the control group, and endothelial function is greatly reduced. These results confirm the effect of connective tissue dysplasia in the structure and function of the arteries.

This discussion article presents necessary information for general practitioners and neurologists concerning vascular brain disorders and post-insult conditions. Also authors discuss aspects of the epidemiology, risk factors, pathogenesis and treatment of stroke, particularly in conservative therapy of stroke, neuroprotective agent of the citicoline (Ceraxon). Case from neurologist practice is shown.

It is well known that cardiac autonomic neuropathy (CAN) is the negative prognostic factor which increases mortality in patients with diabetes mellitus. CAN may have greater predictive power for cardiovascular events than traditional risk factors. Significant morbidity and mortality can now be attributable to autonomic imbalance between the sympathetic and parasympathetic nervous system regulation of cardiovascular function. This review covers the epidemiology, pathophysiology, clinical presentation, and diagnosis of CAN in diabetes and discusses current evidence on approaches to prevention and treatment of CAN.

The prospective, randomized, open-label 16-week trial studied Mexicor ® (part of complex treatment) effects in patients with chronic heart failure and type 2 diabetes mellitus, on structural and functional parameters of the liver. Hepatoprotecive facilities of Mexicor ® were demonstrated: a significant decrease in the severity of cytolysis, cholestasis, steatosis index, the ability to reduce severity of structural changes in the liver by ultrasound. These hepatoprotective effects are realized by Mexicor ® influencing on lipid peroxidation, activity of antioxidant enzymes, decreasing of chronic systemic inflammation expressions. The use of Mexicor ® promotes more evident associated hypoglycemic effect and reduces the severity of insulin resistance. Marked hepatoprotective effects of Mexicor ® improves not only metabolic processes in the liver, but also can significantly change the cardiovascular risk in these patients.

According to modern researches data, patients with cardiovascular diseases often suffer from symptoms of anxiety-phobic, panic, somatoform disorders and hypochondria. One of the most common signs of psychopathological disorders in patients with cardiovascular diseases are anxiety symptoms. Development and introduction into clinical practice of new Russian anxiolytic Afobazol had opened new perspectives in the treatment of those patients.